CellPath: Clinically relevant

As companies try to minimize the risk of compounds failing in clinical trials, it is essential to find drug discovery assays that are more predictive of success. CellPath Inc. believes that using tissue from human patients to screen compounds for activity is the next best thing to actual testing in patients and the best way to find compounds that will work in clinical trials.

CellPath uses normal tissues from patients to compare responses with diseased tissue. This differential screening allows the company to identify active compounds and eliminate non-specific compounds or those with toxic side effects...